Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sisram Medical Ltd. ( (HK:1696) ) has provided an update.
Sisram Medical Ltd has entered into a Supply Framework Agreement with Fosun Wanbang (Jiangsu) to supply botulinum toxin type A for injection, known as DAXXIFY®, in Mainland China. This agreement aligns with Sisram’s business model and is expected to generate additional revenue, enhancing its market position. The collaboration with Fosun Wanbang, a qualified institution for distributing medical toxins in China, is strategically beneficial due to its independence from competitors and nationwide distribution capabilities. This partnership supports Sisram’s long-term commercial planning and operational efficiency.
More about Sisram Medical Ltd.
Sisram Medical Ltd is a leading global provider of energy-based medical aesthetic treatment systems. The company has comprehensive in-house capabilities to design, develop, and produce these systems, featuring innovative and proprietary technologies. As the primary platform for medical aesthetic treatment systems within the Fosun Pharma Group, Sisram Medical is well-positioned in the market.
Average Trading Volume: 1,078,492
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.26B
For an in-depth examination of 1696 stock, go to TipRanks’ Stock Analysis page.